Synapse - Adult Leukemia

Results (3712)

A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients

Meeting Abstract

Zeidan, A. M.; Sekeres, M. A.; Al-Samkari, H.; Carraway, H. E.; DeZern, A. E.; Mittelman, M.; Little, M.; Beynon, V.; Dai, X.; Sommakia, S.; more...
Blood (2024)

Fulltext@MSK | Save

First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Meeting Abstract

Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
Blood (2024)

Fulltext@MSK | Save

Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
Blood (2024)

Fulltext@MSK | Save

Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia

Meeting Abstract

Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
Blood (2024)

Fulltext@MSK | Save

Two decade single institution experience highlights rare survivors with relapsed or refractory Burkitt lymphoma

Meeting Abstract

Molla, R.; Berman, E.; Caron, P.; Donnelly, G.; Falchi, L.; Hamlin, P. A.; Horwitz, S.; Intlekofer, A. M.; Johnson, W. T.; Jurcic, J. G.; more...
Blood (2024)

Fulltext@MSK | Save

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS